公开(公告)号：US20240140959A1

公开(公告)日：2024-05-02

申请号：US18497296

申请日：2023-10-30

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James Anthony NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D491/107 ,  A61K45/06 ,  A61P25/18

CPC classification number: C07D491/107 ,  A61K45/06 ,  A61P25/18

Abstract: Provided herein are compounds according to Formula (I)




or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US20230212139A1

公开(公告)日：2023-07-06

申请号：US18062356

申请日：2022-12-06

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D401/04

CPC classification number: C07D401/04 ,  A61K45/06

Abstract: Provided herein are compounds according to Formula (I)




or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US20220411435A1

公开(公告)日：2022-12-29

申请号：US17818321

申请日：2022-08-08

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D491/107 ,  A61P25/18 ,  A61K45/06

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US20210130365A1

公开(公告)日：2021-05-06

申请号：US17065367

申请日：2020-10-07

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D491/107 ,  A61K45/06 ,  A61P25/18

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US20250145600A1

公开(公告)日：2025-05-08

申请号：US18836800

申请日：2023-02-10

Applicant: Novartis AG

Inventor： Martin ALLAN ,  Matthew CARSON ,  Thomas CAYA ,  Tanzina FAZAL ,  Ming QIAN ,  Troy SMITH ,  Liansheng SU ,  Lihua YANG ,  Ping ZHANG

IPC: C07D413/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K45/06 ,  C07D405/14 ,  C07D417/14

Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds, as well as methods and uses of these compounds in the treatment of diseases.

公开(公告)号：US20240182456A1

公开(公告)日：2024-06-06

申请号：US18554778

申请日：2022-04-11

Applicant: Novartis AG

Inventor： Martin ALLAN ,  Matthew CARSON ,  Thomas CAYA ,  Lara CZABANIUK ,  Ming QIAN ,  Daniel SMITH ,  Troy SMITH ,  Liansheng SU ,  Chung-Yeh WU ,  Lihua YANG ,  Chun ZHANG ,  Ping ZHANG ,  Xilin ZHOU

IPC: C07D405/14 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention relates to compounds of formula (I) as activators of glucagon-like peptide 1 (GLP1) receptor for the treatment of obesity, type 2 diabetes mellitus, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, one or more diabetic complications, diabetic nephropathy, dyslipidemia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hypertension, atherosclerosis, peripheral arterial disease, stroke, cardiomyopathy, atrial fibrillation, heart failure, coronary heart disease and neuropathy. Preferred compounds are e.g. 2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-imidazole derivatives and similar compounds, such as e.g. C-1, C-2, C-3, C-4 and other compounds.

公开(公告)号：US20210107889A1

公开(公告)日：2021-04-15

申请号：US17065360

申请日：2020-10-07

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D401/04

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.